Sanofi To Cut Drug Prices In South East Asia In Experiment Aimed At Creating A Sustainable Model Of Access
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Sanofi-Aventis hopes to widen the availability of its medicines in less developed nations by slashing the price of some drugs in Southeast Asia, in a move that could be modeled after a similar program launched by GlaxoSmithKline one year ago
You may also be interested in...
Graham Almond On Sanofi’s Plans to Build Zentiva Generics Brand In Southeast Asia: An Interview With PharmAsia News (Part 1 of 2)
PharmAsia News talks with Sanofi Vice President Southeast Asia, Global Operations Graham Almond to see how the company, with a long-standing presence in the region, is dealing with expansions in public health care coverage to grow its generics business.
New Wave Of Cancer Drugs Puts Hard Focus On Need For Inexpensive Screening
Stunning advances in cancer therapies have sharpened the need for low-cost gene sequencing to identify the right patients for the right drugs, especially in Asia, frontline cancer experts say.
New Wave Of Cancer Drugs Puts Hard Focus On Need For Inexpensive Screening
Stunning advances in cancer therapies have sharpened the need for low-cost gene sequencing to identify the right patients for the right drugs, especially in Asia, frontline cancer experts say.